Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Its news flow reflects both scientific progress and corporate developments, making the MRSN news page a focused source for investors and observers following oncology drug development and transaction activity.
Company press releases emphasize updates from its ADC pipeline, particularly Emi-Le (emiltatug ledadotin; XMT-1660), a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope. News items have covered interim Phase 1 clinical data for Emi-Le in triple-negative breast cancer and adenoid cystic carcinoma type 1, including objective response rates and safety observations, as well as plans for dose expansion cohorts and future data readouts. Additional scientific news includes presentations at major oncology congresses such as ASCO and ESMO Breast Cancer.
Mersana’s news releases also detail collaboration milestones with partners including GSK, Janssen Biotech, Inc. (Johnson & Johnson) and Merck KGaA, Darmstadt, Germany. Examples include the achievement of development milestone payments and FDA clearance of an investigational new drug application for a Dolasynthen ADC developed under a collaboration. Corporate and capital markets news has included announcements of quarterly financial results, a 1-for-25 reverse stock split designed to support Nasdaq listing compliance, and notices related to Nasdaq listing standards.
A significant portion of recent news is devoted to the proposed acquisition of Mersana by Day One Biopharmaceuticals, Inc., including the terms of the tender offer, the structure of the contingent value rights and the expected timing of closing. Readers of the MRSN news page can therefore expect a mix of clinical trial updates, collaboration developments, financial disclosures, listing-related actions and transaction announcements. For ongoing context around these events, this page can be revisited as new company communications are released.
Mersana Therapeutics (NASDAQ:MRSN) announced on April 1, 2022, the grant of inducement awards consisting of stock options for 51,150 shares to four new employees. These options have an exercise price of $4.32 per share, equal to the closing price on the grant date. The options vest over four years, with 25% vesting on the one-year anniversary and the rest vesting quarterly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the clinical-stage biopharmaceutical company, which focuses on innovative antibody-drug conjugates targeting cancer.
Mersana Therapeutics (NASDAQ:MRSN) has announced promising results for XMT-1660 and XMT-2056, two antibody-drug conjugates (ADCs) targeting cancer. XMT-1660 showed robust anti-tumor activity in breast cancer models, particularly in B7-H4 expressing tumors, while XMT-2056 demonstrated effectiveness as a monotherapy and in combination with standard therapies in HER2-positive models. Both candidates are set to enter Phase 1 clinical trials in mid-2022. The company will present relevant data at the AACR Annual Meeting from April 8-13, 2022. This progress signals potential advancements in cancer treatment.
Mersana Therapeutics (NASDAQ:MRSN) announced the presentation of data from its Phase 1 trial of upifitamab rilsodotin (UpRi) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, March 18-21, 2022. UpRi targets NaPi2b in patients with platinum-resistant ovarian cancer. Analysis on nearly 100 patients, presented on March 19, supports a recommended Phase 2 dose of 36 mg/m² for the ongoing UPLIFT trial. Mersana plans to initiate a Phase 3 trial (UP-NEXT) for UpRi monotherapy maintenance in platinum-sensitive recurrent ovarian cancer in Q2 2022.
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on cancer therapies, will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET. The presentation will be accessible via a live webcast on their website, with an archived replay available for 30 days. Mersana's lead candidate, upifitamab rilsodotin, is being evaluated in pivotal trials for ovarian cancer, while the company continues to develop additional antibody drug conjugates (ADCs) targeting NaPi2b and other cancer-related pathways.
Mersana Therapeutics (MRSN) reported its Q4 and full-year 2021 financial results, highlighting a net loss of $49 million for Q4 and $170 million for the year. The company is advancing multiple antibody-drug conjugates (ADCs) targeting cancers, with key trials like UPLIFT and UP-NEXT on track. A strategic collaboration with Janssen brought in $40 million upfront and potential future milestones exceeding $1 billion. Cash and equivalents stood at $177.9 million as of year-end 2021, with the company expecting sufficient funds into H2 2023.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced a conference call on February 28, 2022, at 8:00 a.m. ET to discuss its Q4 and annual financial results for 2021 and provide business updates. The company focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with lead candidate upifitamab rilsodotin undergoing clinical trials for ovarian cancer. Mersana also develops additional ADCs and collaborates with partners to enhance their ADC pipelines. The firm was recognized as one of Massachusetts's top workplaces in 2021.
Mersana Therapeutics, focused on developing antibody drug conjugates (ADCs), will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. This event will be accessible via a live webcast on their website, with an archived replay available for 30 days. The company is advancing its lead ADC, upifitamab rilsodotin (UpRi), for platinum-resistant ovarian cancer, along with other promising candidates using its proprietary platforms.
Mersana Therapeutics (NASDAQ:MRSN) announced a collaboration with Janssen Biotech to discover novel antibody-drug conjugates (ADCs) targeting three cancer-related proteins. The agreement includes a $40 million upfront payment, with the potential for over $1 billion in milestones and royalties. Mersana will utilize its Dolasynthen platform to develop ADCs using Janssen's proprietary antibodies. This collaboration aims to enhance Mersana's financial position while expanding its pipeline in cancer treatment.
Mersana Therapeutics (MRSN) provided updates on its strategic initiatives and clinical trials in its latest press release. The company aims to establish UpRi as a foundational treatment for ovarian cancer, with the UPLIFT trial expected to complete enrollment in Q3 2022. Upcoming trials include UP-NEXT, a Phase 3 study, slated to start in Q2 2022, and UPGRADE, with interim data expected in H2 2022. Additionally, Phase 1 trials for XMT-1660 and XMT-2056 are set to begin in mid-2022. Mersana emphasizes its innovative ADC platform and plans to disclose new candidates in 2022.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:00 p.m. ET. CEO Anna Protopapas will lead the presentation. A live webcast will be available on the company's website, with an archived replay accessible for 30 days. Mersana focuses on developing antibody drug conjugates (ADCs) for cancer treatment, notably its lead candidate, upifitamab rilsodotin, targeting platinum-resistant ovarian cancer. The company also has several other promising ADC candidates.